Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03128047 · ClinicalTrials.gov registry record · Phase 1
HUMC 1612: Optune NovoTTF-200A System
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03128047 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 7 participants.
The verdict
NCT03128047, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
Interventions
- DEVICE Optune NovoTTF-200A System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2025-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03128047
The ClinicalTrials.gov registry entry for NCT03128047 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Optune NovoTTF-200A System is the first listed.
NCT03128047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03128047 about?
NCT03128047 is a clinical study titled "HUMC 1612: Optune NovoTTF-200A System". The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.
What is the current status of trial NCT03128047?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-04-06. Estimated completion is 2025-04-05.
What interventions are being tested in trial NCT03128047?
The interventions under investigation include: Optune NovoTTF-200A System (DEVICE).
Who is sponsoring clinical trial NCT03128047?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.